• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Tom Wall

Articles by Tom Wall

Opportunities in China, India Have Legal, Regulatory Hurdles

Nov. 10, 2011
By Tom Wall
Western biopharmaceutical companies hoping to capitalize on opportunities in the emerging China and India markets through collaborations and partnerships should be prepared to deal with potential legal and regulatory challenges related to intellectual property (IP), accounting and import-export standards.
Read More

Quanticel, Celgene and Versant Ink $45M Cancer Collaboration

Nov. 7, 2011
By Tom Wall
Quanticel Pharmaceuticals Inc., a fledgling, privately held San Francisco biotech, Celgene Corp., of Summit, N.J., and California venture capital firm Versant Ventures have agreed to a 3.5-year, $45 million "build to buy" cancer drug collaboration.
Read More

Medivation Shares up 140% On Positive MDV3100 Results

Nov. 4, 2011
By Tom Wall
Medivation Inc. stock doubled and then some following an announcement by the San Francisco-based biotech and partner Astellas Pharma Inc., of Tokyo, that results from an interim analysis of the Phase III AFFIRM trial of MDV3100 in men with advanced prostate cancer were so positive that the independent data monitoring committee recommended the trial be stopped and MDV3100 offered to the men who received placebo.
Read More

No SPA for Cabo Phase III in CRPC; Exelixis Plummets

Nov. 2, 2011
By Tom Wall
Exelixis Inc.'s stock plummeted 40.2 percent Tuesday following the South San Francisco biotech's announcement that it was unable to secure a special protocol assessment (SPA) from the FDA for its pivotal Phase III XL184-306 trial of cabozantinib (cabo) in end-stage castrate resistant prostate cancer (CRPC).Exelixis said it has stopped pursuing the SPA and plans to initiate the '306 trial by the end of 2011 with pain as the primary efficacy endpoint, to be followed in the first half of 2012 by the Phase III XL184-307 trial to evaluate overall survival time.
Read More

Omeros Goes Down Hard After Blowing Out ACL Trial

Oct. 31, 2011
By Tom Wall
Omeros Corp. went down hard following news that the Seattle-based company's lead candidate OMS103HP did not meet endpoints in Phase III trials evaluating its ability to improve postoperative joint motion and function and reduce postoperative pain in patients who'd undergone arthroscopic anterior cruciate ligament (ACL) reconstruction surgery.
Read More

Comeback Continues with Palatin's $21.1M Offering

Oct. 31, 2011
By Tom Wall
Palatin Technologies Inc. continued its comeback efforts by pricing an underwritten public offering of 23 million units of stock and warrants at $1 per unit, about 4 percent less than Wednesday's closing price. The offering is expected to net about $21.1 million – enough to get the company through the end of 2012 – with proceeds intended for a Phase II trial of bremelanotide for female sexual dysfunction, development of PL-3994 for asthma and development of new peptides for sexual dysfunction.
Read More

Vertex Rings its 1st Profit Bell After Incivek's 3Q Surge

Oct. 31, 2011
By Tom Wall
Vertex Pharmaceuticals Inc. reported its first-ever profitable quarter built on better-than-expected sales of hepatitis C drug Incivek (telaprevir).
Read More

Benlysta Sales, New Guidance Send HGSI Shares Down 22%

Oct. 27, 2011
By Tom Wall
A trifecta of investor-unsettling news sent Human Genome Sciences Inc.
Read More

Amgen Furloughs 380, Shifts Resources to Late-Stage Programs

Oct. 21, 2011
By Tom Wall
Amgen Inc. will lay off about 380 employees at several R&D sites and shift resources to several late-stage programs. The furloughs, effective Dec. 30, involve about 2 percent of the giant biotech's roughly 17,600 employees worldwide.
Read More

Topica Raises $27M Series B For Nail Antifungal Trial

Oct. 19, 2011
By Tom Wall
There's a lot of toenail and fingernail fungus among us, enough that Topica Pharmaceuticals Inc., has raised $27 million in a Series B financing to support a Phase IIb/III trial of the privately held Palo Alto, Calif.-based biotech's luliconazole topical antifungal agent for treatment of onychomycosis.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 15 16 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe